Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

News SummaryMost relevantAll newsSector newsTweets 

UK Health Watchdog Backs Lung Cancer Drug From Roche

share with twitter share with LinkedIn share with facebook
share via e-mail
05/10/2012 | 01:16am CEST

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; [email protected]

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA PLC
04/25 ASTRAZENECA : marks a key milestone with the ‘topping out’ of new gl..
04/25DJASTRAZENECA : Lung Cancer Treatment Approved in EU
04/25 ASTRAZENECA : Gets European Marketing Approval For Tagrisso
04/25 ASTRAZENECA : Tagrisso receives full approval in the EU
04/24 ASTRAZENECA : Q1 2017 Results media conference
04/22 ASTRAZENECA : NCATS Announces Funding Opportunities to Repurpose Existing Drugs ..
04/21 ASTRAZENECA : *jefferies cuts astrazeneca price target to 4900 pence - 'hold'
04/20 ASTRAZENECA : Creating the ‘google earth’ of tumours
04/20 ASTRAZENECA : Circassia gives up on allergy treatments after second trial failur..
04/19 ASTRAZENECA : BioHealth Innovation, VirginiaBio, Paragon Bioservices, INOVA, the..
More news
Sector news : Pharmaceuticals - NEC
04/25DJSHIRE : Files 8K - Other Events
04/25DJSHIRE : Files 8K - Changes To Articles
04/25DJNasdaq Composite Tops 6000 for First Time
04/25DJELI LILLY AND : Working to Cut Costs
04/25 Fresenius picks up M&A pace with Akorn, Merck KGaA deals
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/25 5 YEARS IN SEEKING ALPHA'S 'DGI FUN : Mistakes Made, Lessons Learned - And Triu..
04/24 A Physician Analyzes Valeant's Siliq, As The Stock Crashes
04/21 Bristol's Search For Yervoy Mark II
04/21 Abbvie's Parp Runs Out Of Puff
04/21 Merck Leads Rivals In Novel Drug Approvals
Financials ($)
Sales 2017 21 483 M
EBIT 2017 6 026 M
Net income 2017 2 529 M
Debt 2017 12 289 M
Yield 2017 4,57%
P/E ratio 2017 26,78
P/E ratio 2018 21,88
EV / Sales 2017 4,09x
EV / Sales 2018 3,95x
Capitalization 75 602 M
More Financials
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 63,0 $
Spread / Average Target 5,6%
Consensus details
EPS Revisions
More Estimates Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON6.67%333 142
ROCHE HOLDING LTD.8.21%220 797
PFIZER INC.3.88%200 926
NOVARTIS AG-1.08%195 490
MERCK & CO., INC.5.55%170 359
More Results